Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

siltuximab 1ruxolitinib 1pelcitoclax 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Thrombocytosis × ruxolitinib × Clear all
NCT04354727 2022-07-12

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Ascentage Pharma Group Inc.

Phase 1/2 Withdrawn
Myeloid

Polycythemia Vera, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡